Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma

Cancer Science

Volumn 105, Issue 6, 2014, Pages 713-722

  Siddiquey, Mohammed N A ^a   Nakagawa, Hikaru ^a   Iwata, Seiko ^a   Kanazawa, Tetsuhiro ^a   Suzuki, Michio ^a   Imadome, Ken Ichi ^b   Fujiwara, Shigeyoshi ^b   Goshima, Fumi ^a   Murata, Takayuki ^a   Kimura, Hiroshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Extranodal NK T cell lymphoma; Histone deacetylase inhibitor; Human herpesvirus 4; Hydroxamic acid; SCID mice

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; INTERLEUKIN 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CAPSULE; KIDNEY PARENCHYMA; LYMPHOCYTE PROLIFERATION; METASTASIS; MOUSE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; T CELL LYMPHOMA; TUMOR GROWTH;

EXTRANODAL NK-T-CELL LYMPHOMA; HISTONE DEACETYLASE INHIBITOR; HUMAN HERPESVIRUS 4; HYDROXAMIC ACID; SCID MICE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901754054     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12418     Document Type: Article

References (42)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-92.
2. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107: 862-9.
3. Suzuki R, Suzumiya J, Yamaguchi M et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21: 1032-40.
4. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-42.
5. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-8.
6. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
7. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-52.
8. Iwata S, Saito T, Ito Y et al. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer Sci 2012; 103: 375-81.
9. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001; 27: 260-4.
10. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351-6.
11. Stathis A, Hotte SJ, Chen EX et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011; 17: 1582-90.
12. Munster PN, Thurn KT, Thomas S et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828-35.
13. Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer 2010; 126: 2479-89.
14. Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer 2012; 131: 1930-40.
15. Karube K, Tsuzuki S, Yoshida N et al. Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate. Cancer Lett 2013; 333: 47-55.
16. Ito M, Hiramatsu H, Kobayashi K et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-82.
17. Yajima M, Imadome K, Nakagawa A et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008; 198: 673-82.
18. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-89.
19. Sato K, Misawa N, Nie C et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011; 117: 5663-73.
20. Imadome K, Yajima M, Arai A et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 2011; 7: e1002326.
21. Zhang Y, Nagata H, Ikeuchi T et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003; 121: 805-14.
22. Kaplan J, Tilton J, Peterson WD. Identification of T cell lymphoma tumor antigens on human T cell lines. Am J Hematol 1976; 1: 219-23.
23. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115: 385-92.
24. Yagita M, Huang CL, Umehara H et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000; 14: 922-30.
25. Miyoshi I, Kubonishi I, Yoshimoto S et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 770-1.
26. Fujiwara S, Ono Y. Isolation of Epstein-Barr virus-infected clones of the human T-cell line MT-2: use of recombinant viruses with a positive selection marker. J Virol 1995; 69: 3900-3.
27. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406-15.
28. Isobe Y, Sugimoto K, Matsuura I, Takada K, Oshimi K. Epstein-Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis. Br J Cancer 2008; 99: 1816-22.
29. Iwata S, Yano S, Ito Y et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int J Cancer 2011; 129: 2263-73.
30. Wang D, Liebowitz D, Wang F et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988; 62: 4173-84.
31. Daikoku T, Kudoh A, Fujita M, Sugaya Y, Isomura H, Tsurumi T. In vivo dynamics of EBNA1-oriP interaction during latent and lytic replication of Epstein-Barr virus. J Biol Chem 2004; 279: 54817-25.
32. Iwata S, Wada K, Tobita S et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol 2010; 91: 42-50.
33. Kubota N, Wada K, Ito Y et al. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection. J Virol Methods 2008; 147: 26-36.
34. Patel K, Whelan PJ, Prescott S et al. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 2004; 10: 7511-9.
35. Murata T, Iwata S, Siddiquey MN et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS ONE 2013; 8: e63566.
36. Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132-6.
37. Longnecker RM, Kieff E, Cohen JI. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields Virology, 6th edn. Philadelphia: Wolters kluwer/Lippincott Williams & Wilkins, 2013; 1898-959.
38. Damania B. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004; 2: 656-68.
39. Saridakis V, Sheng Y, Sarkari F et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 2005; 18: 25-36.
40. Mahalingam D, Medina EC, Esquivel JA et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010; 16: 141-53.
41. Thelen P, Krahn L, Bremmer F, Strauss A, Brehm R, Loertzer H. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma. Int J Mol Med 2013; 31: 339-46.
42. Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther 2013; 12: 747-58.